Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | CDK2 | P24941 | 6/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | GAA | P10253 | 6/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1684787 | 0.81 | ALDH1A1 (0.51) | MAPTKDM4ELMNAMAPK1HTT | |
| SCHEMBL1684880 | 0.79 | MAPT (0.48) | MAPTKDM4ELMNAMAPK1HTT | |
| SCHEMBL1684823 | 0.77 | ALDH1A1 (0.53) | MAPTKDM4ELMNAMAPK1HTT | |
| SCHEMBL18100941 | 0.73 | MAPT (0.50) | MAPTKDM4ELMNAMAPK1HTT | |
| SCHEMBL1684609 | 0.68 | MAPT (0.67) | MAPTKDM4ELMNAMAPK1HTT | |
| SCHEMBL18104238 | 0.68 | KDM4E (0.55) | MAPTKDM4ELMNAMAPK1HTT | |
| SCHEMBL1684486 | 0.67 | MAPT (0.73) | MAPTKDM4ELMNAMAPK1HTT | |
| SCHEMBL18100932 | 0.67 | MAPT (0.46) | MAPTKDM4ELMNAMAPK1HTT | |
| SCHEMBL2355015 | 0.67 | CDK2 (0.60) | MAPTKDM4ELMNAHTTCDK2 | |
| SCHEMBL1684741 | 0.67 | CDK2 (0.60) | MAPTKDM4ELMNAHTTCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2306836-B1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS INC (US) | 2016-09-07 | — | — | EP | claimed |
| US-8680113-B2 | BMI-1 protein expression modulators | PTC THERAPEUTICS, INC. (US) | 2014-03-25 | — | — | US | claimed |
| US-20110190239-A1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS, INC. (US) | 2011-08-04 | — | — | US | claimed |
| EP-2306836-A1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC Therapeutics, Inc. (US) | 2011-04-13 | — | — | EP | claimed |
| WO-2010002985-A1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS, INC. (US) | 2010-01-07 | — | — | WO | claimed |
| EP-3111956-B1 | BMI 1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS INC (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-3111956-A1 | BMI 1 PROTEIN EXPRESSION MODULATORS | PTC Therapeutics, Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-2306836-B1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS INC (US) | 2016-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190239-A1 | BMI-1 PROTEIN EXPRESSION MODULATORS | BMI1, CREBBP, BAZ2A | MAPT 4026/4885KDM4E 152/4885LMNA 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.